The chymase inhibitor significantly prevented hepatic steatosis, fibrosis, and inflammatory cell accumulation in this NASH model (Tashiro et al., 2010; Masubuchi et al., 2013). This evidence concerns the gene CMA1 and metabolic dysfunction-associated steatohepatitis.